<DOC>
	<DOCNO>NCT02191670</DOCNO>
	<brief_summary>Primary : To support Regulatory Approval process Metalyse® Russian Federation . Secondary : To assess efficacy safety single bolus Metalyse® TNK-tissue plasminogen activator ( TNK-tPA , Tenecteplase ) patient acute myocardial infarction usual routine treatment market launch</brief_summary>
	<brief_title>Observational Study METALYSE® Patients With Acute Myocardial Infarction In Russian Federation</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Tenecteplase</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>onset symptom AMI within 6 hour twelvelead electrocardiogram ( ECG ) , STsegment elevation ≥ 0.1 millivolt ( mV ) two limb lead , &gt; 0.2 mV two contiguous precordial lead indicative AMI , leave bundlebranch block age ≥ 18 significant bleed disorder present within past 6 month , know hemorrhagic diathesis patient current concomitant oral anticoagulant therapy International Normalised Ratio ( INR ) &gt; 1.3 history central nervous system damage ( i.e . neoplasm , aneurysm , intracranial spinal surgery ) severe uncontrolled arterial hypertension ( hypertension define blood pressure 180/110 mm Hg ( systolic BP &gt; 180 mm Hg and/or diastolic BP &gt; 100 mm Hg ) one single reliable measurement current admission prior study enrolment major surgery , biopsy parenchymal organ , significant trauma within past 2 month ( include trauma associate current AMI ) , recent trauma head cranium prolong traumatic cardiopulmonary resuscitation ( &gt; 2 minute ) within past 2 week severe hepatic dysfunction , include hepatic failure , cirrhosis , portal hypertension ( esophageal varix ) active hepatitis diabetic hemorrhagic retinopathy hemorrhagic ophthalmic condition active peptic ulceration arterial aneurysm know arterial/venous malformation neoplasm increase bleed risk Acute pericarditis and/or subacute bacterial endocarditis Acute pancreatitis hypersensitivity active substance tenecteplase excipients use Abciximab ( ReoPro® ) market GPIIb/IIIa antagonist within precede 12 hour minor head trauma trauma occur onset current myocardial infarction know history stroke transient ischemic attack dementia pregnancy lactation , parturition within previous 30 day . Women childbearing potential must negative pregnancy test know active participation another investigative drug study device protocol past 30 day previous enrollment study inability follow protocol comply followup requirement condition investigator feel would place patient increase risk investigational therapy initiate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>